Oral candidiasis

Summary

Oral candidiasis (MONDO:0005886) is a disease and 8 clinical trials. Top therapeutic interventions include clotrimazole, fluconazole, and lactobacillus acidophilus. A subtype of candidiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	oral candidiasis
Mondo ID	MONDO:0005886
EFO	EFO:0007406
MeSH	D002180
DOID	DOID:14262
NCIT	C28137
SNOMED CT	79740000
UMLS	C0006849
MedGen	14300
Anatomy (UBERON)	UBERON:0000165
Is cancer (heuristic)	no

Also known as: candidiasis of mouth · mouth candidiasis · thrush

Disease family

This is a subtype of candidiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › opportunistic mycosis › candidiasis › oral candidiasis

Related subtypes (8): cutaneous candidiasis, esophageal candidiasis, candidal paronychia, neonatal candidiasis, candida glabrata infection, congenital candidiasis, disseminated candidiasis, candidiasis, invasive

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 6 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Caspofungin	Phase 3 (in late-stage trials)
Clotrimazole	Phase 3 (in late-stage trials)
Fluconazole	Phase 3 (in late-stage trials)
Micafungin	Phase 3 (in late-stage trials)
Nystatin	Phase 3 (in late-stage trials)
Posaconazole	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00001542	PHASE4	COMPLETED	Fluconazole Prophylaxis of Thrush in AIDS
NCT00659971	PHASE2	COMPLETED	Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis
NCT00835029	PHASE2	COMPLETED	Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches
NCT05289375	Not specified	NOT_YET_RECRUITING	Efficacy of the Vacucis Candida® Autovaccine
NCT00612963	Not specified	COMPLETED	Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
NCT00768794	Not specified	COMPLETED	Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation Therapy
NCT01237782	Not specified	COMPLETED	Efficacy of a Propolis-based Denture Cleanser
NCT01237795	Not specified	COMPLETED	Experimental Denture Pastes

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLOTRIMAZOLE	4	1
FLUCONAZOLE	4	1
LACTOBACILLUS ACIDOPHILUS	3	1